Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1920 1
1921 1
1924 1
1925 1
1926 1
1930 1
1931 1
1932 1
1933 1
1934 1
1935 1
1939 1
1942 1
1947 2
1948 1
1949 3
1950 1
1951 4
1952 1
1953 1
1956 1
1960 1
1962 1
1963 2
1964 1
1965 15
1966 41
1967 36
1968 37
1969 25
1970 39
1971 2
1972 1
1973 28
1974 24
1975 22
1976 28
1977 36
1978 47
1979 51
1980 37
1981 8
1982 8
1983 9
1984 6
1985 10
1986 5
1987 14
1988 12
1989 5
1990 12
1991 7
1992 17
1993 14
1994 13
1995 18
1996 12
1997 13
1998 17
1999 15
2000 14
2001 19
2002 15
2003 23
2004 24
2005 15
2006 31
2007 35
2008 38
2009 35
2010 20
2011 27
2012 34
2013 33
2014 38
2015 33
2016 41
2017 37
2018 47
2019 53
2020 69
2021 75
2022 73
2023 76
2024 66

Text availability

Article attribute

Article type

Publication date

Search Results

1,589 results

Results by year

Filters applied: . Clear all
Page 1
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Freeman GJ, et al. Among authors: carter l. J Exp Med. 2000 Oct 2;192(7):1027-34. doi: 10.1084/jem.192.7.1027. J Exp Med. 2000. PMID: 11015443 Free PMC article.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. Latchman Y, et al. Among authors: carter ll. Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527
NAL-NL2 empirical adjustments.
Keidser G, Dillon H, Carter L, O'Brien A. Keidser G, et al. Among authors: carter l. Trends Amplif. 2012 Dec;16(4):211-23. doi: 10.1177/1084713812468511. Epub 2012 Nov 30. Trends Amplif. 2012. PMID: 23203416 Free PMC article. Review.
Editorial.
Carter L. Carter L. J Anal Psychol. 2012 Nov;57(5):573-5. doi: 10.1111/j.1468-5922.2012.02003.x. J Anal Psychol. 2012. PMID: 23130613 No abstract available.
Management of asymptomatic carotid atherosclerosis.
Martin NA, Hadley MN, Spetzler RF, Carter LP. Martin NA, et al. Among authors: carter lp. Neurosurgery. 1986 Apr;18(4):505-13. doi: 10.1227/00006123-198604000-00026. Neurosurgery. 1986. PMID: 3517677 Review.
Resveratrol and cancer: focus on in vivo evidence.
Carter LG, D'Orazio JA, Pearson KJ. Carter LG, et al. Endocr Relat Cancer. 2014 May 6;21(3):R209-25. doi: 10.1530/ERC-13-0171. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24500760 Free PMC article. Review.
Hot potato speech.
Carter LM, Varley I. Carter LM, et al. Br Dent J. 2007 Jul 28;203(2):63. doi: 10.1038/bdj.2007.648. Br Dent J. 2007. PMID: 17660760 No abstract available.
Addiction, neuroscience and ethics.
Hall W, Carter L, Morley KI. Hall W, et al. Among authors: carter l. Addiction. 2003 Jul;98(7):867-70. doi: 10.1046/j.1360-0443.2003.00400.x. Addiction. 2003. PMID: 12814489 Free article. No abstract available.
1,589 results